Document Type : Review Articles
Authors
1
ksa,Ministry of Health, abu areesh middle sector /Jazan
2
ksa,Ministry of Health, Supply chains/ Jazan Health Cluster
3
ksa,Ministry of Health, supply chains /Jazan Health Cluster
4
ksa,Ministry of Health, Ahad almsarha hospital
5
ksa,Ministry of Health, Compliance management
6
ksa,Ministry of Health, Primary care centre in Alfakrah
7
ksa,Ministry of Health, king fahad hopspital -pharmacy
8
ksa,Ministry of Health, King Fahad Hospital-pharmacy
9
ksa,Ministry of Health
10
ksa,Ministry of Health, King Fahad Hospital in Jazan
11
ksa,Ministry of Health, King fahd central Hospital in jazan
12
ksa,Ministry of Health, GAZAN HEALTH CLUSTER
Abstract
Background:
The drug discovery and development process has traditionally been one of the most challenging and resource-intensive endeavours in the pharmaceutical industry. On average, bringing a single drug from concept to market takes over a decade and costs approximately $2.6 billion. These processes are further hindered by high attrition rates, particularly in clinical trials, which contribute to the escalating cost and time. This inefficiency is largely attributed to the complexity of biological systems and the limitations of existing empirical methodologies. Over recent years, Artificial Intelligence (AI) has emerged as a powerful tool capable of transforming the drug development landscape. AI leverages computational algorithms, machine learning models, and data-driven approaches to overcome traditional bottlenecks in drug discovery. With capabilities spanning target identification, lead optimization, drug repurposing, and clinical trial design, AI is reshaping the future of pharmaceutical innovation.
Aim:
This paper provides a comprehensive examination of the role of AI in drug discovery and development. It explores the methodologies and tools employed by AI, evaluates key successes achieved in real-world applications, and examines challenges associated with its adoption. By synthesizing advancements and analyzing their impact, this paper aims to illuminate the transformative potential of AI in revolutionizing the pharmaceutical industry.
Methods:
The study adopts a robust methodological approach, relying on a critical review of recent literature published between 2015 and 2024. It integrates findings from academic research, industrial case studies, and regulatory perspectives to provide a holistic understanding of AI's impact across the drug development pipeline. Comparative analysis highlights the efficiencies of AI-driven approaches relative to traditional methods, with an emphasis on specific applications such as deep learning, reinforcement learning, and natural language processing (NLP).
Results:
AI applications have demonstrated measurable success across multiple domains of drug development. Machine learning models have expedited the identification of novel drug targets by analyzing high-dimensional omics data. Deep learning algorithms have revolutionized lead optimization by accurately predicting molecular properties and their pharmacological profiles. AI-driven platforms have also advanced drug repurposing, as evidenced by rapid therapeutic identification during the COVID-19 pandemic. Furthermore, in the realm of clinical trials, AI has significantly improved patient stratification, optimized trial protocols, and enhanced predictive analytics for outcomes. These breakthroughs have collectively reduced both the time and cost of drug development while increasing the likelihood of successful outcomes.
Conclusion:
AI is transforming the pharmaceutical industry, offering unparalleled solutions to challenges that have long plagued drug discovery and development. By integrating large-scale datasets, enhancing chemical design, and optimizing trial processes, AI has established itself as a cornerstone of future innovation. Nevertheless, the successful integration of AI into drug development requires overcoming challenges such as data quality, regulatory compliance, ethical concerns, and the interpretability of AI algorithms. Addressing these barriers is essential to fully realize AI's potential in meeting global healthcare needs. Moving forward, the development of standardized frameworks, interdisciplinary collaborations, and ethical guidelines will be critical in fostering equitable and effective AI-driven drug discovery.
Keywords
Main Subjects
)
View on SCiNiTO